SOLOMON ALLIANCE GROUP, INC. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
E VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Article By: Moon Kil Woong
Friday, January 8, 2021 11:59 AM EST
VistaGen’s deal with Pherin Pharmaceuticals to develop PH-94B has positioned the Company to grab a healthy share of, social anxiety, and major depression markets.
In this article: JNJ, SAGE, CNSP, AXSM, RLMD, VTGN
Read
Sage Shares Below $50, One Of The Best Opportunities In Stifel's Coverage
Article By: The Fly
Sunday, March 1, 2020 3:02 PM EST
Stifel analyst, Paul Matteis says Sage Therapeutics (SAGE) shares below $50 represent one of the best opportunities in Stifel's coverage universe.
In this article: SAGE
Read
Ladenburg Downgrades Sage Therapeutics On Lack Of Near-Term Catalysts
Article By: The Fly
Friday, December 6, 2019 10:16 AM EST
Ladenburg analyst Michael Higgins downgraded Sage Therapeutics to Neutral from Buy with a price target of $60, down from $120.
In this article: SAGE
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EST
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
Sage Therapeutics Slumps As Biogen Deal May Dampen M&A Hopes
Article By: The Fly
Friday, April 20, 2018 2:45 PM EST
Weakness in shares of Sage Therapeutics may be related to news that Biogen and Ionis Pharmaceuticals have expanded their strategic collaboration through a new ten-year collaboration agreement.
In this article: BIIB, SAGE Also: IONS
Read

Latest Tweets for $SAGE

No tweets yet!